Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-06-07
2011-06-07
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C435S007230, C435S008000, C436S064000
Reexamination Certificate
active
07955602
ABSTRACT:
The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
REFERENCES:
patent: 5316915 (1994-05-01), Kraus et al.
patent: 5405749 (1995-04-01), Polans et al.
patent: 5741654 (1998-04-01), Michel et al.
patent: 6645465 (2003-11-01), Hanash et al.
patent: 07072149 (1995-03-01), None
patent: 9900671 (1999-01-01), None
patent: 0039557 (2000-07-01), None
Beer David
Brichory Frank
Hanash Samir M.
Hinderer Robert
Misek David
Arent & Fox LLP
Fetterolf Brandon J
Gembeh Shirley V
Regents of the University of Michigan
LandOfFree
Annexin proteins and autoantibodies as serum markers for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Annexin proteins and autoantibodies as serum markers for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annexin proteins and autoantibodies as serum markers for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2732544